Long-term interferon-alpha therapy induces autoantibodies against epidermis

Dermatology. 1996;192(1):50-5. doi: 10.1159/000246315.

Abstract

Background: While interferon (IFN) is known for its immunoregulatory properties, it has also been shown to induce autoimmune disorders such as lupus erythematosus, hypothyroidism, antiphospholipid syndrome and, recently, bullous pemphigus-like eruptions.

Objective: The purpose of this study was to determine the percentage of antibodies against epidermis induced by IFN-alpha therapy, as detected by indirect immunofluorescence and Western blotting (WB).

Method: We have studied the sera of 47 patients treated with low doses of IFN-alpha 2a for malignant melanoma or cutaneous T cell lymphoma for a period of 12 months. These sera were tested by standard IIF and WB.

Results: 32% of patient sera were positive after 6 months of treatment. Antibodies against epidermis were most often of the pemphigus type as confirmed by WB. Two types of labeling were noted for anti-basement membrane antibodies: basal cytoplasmic pattern in 4 sera and along the dermal side of the basal keratinocytes in 2 sera.

Conclusion: This study brings biological arguments to confirm the direct role of IFN-alpha in the development of pemphigus-like eruption, and emphasizes the need for clinical follow-up of patients treated with IFN-alpha over a long period of time.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Autoantibodies / analysis
  • Autoantibodies / drug effects*
  • Blotting, Western
  • Drug Administration Schedule
  • Epidermis / drug effects*
  • Epidermis / immunology
  • Female
  • Fluorescent Antibody Technique, Indirect
  • Humans
  • Interferon-alpha / administration & dosage*
  • Lymphoma, T-Cell, Cutaneous / drug therapy*
  • Lymphoma, T-Cell, Cutaneous / immunology
  • Male
  • Melanoma / drug therapy*
  • Melanoma / immunology
  • Middle Aged
  • Skin Diseases / drug therapy*
  • Skin Diseases / immunology
  • Time Factors

Substances

  • Autoantibodies
  • Interferon-alpha